Triple Drug Therapy for Kidney Cancer
Trial Summary
Do I need to stop my current medications for the trial?
The trial protocol does not specify if you need to stop your current medications. However, you cannot have had any systemic therapy for kidney cancer within 4 weeks before starting the trial, and certain medications like herbal therapies must be stopped at least 1 week before. It's best to discuss your specific medications with the trial team.
What data supports the effectiveness of the drugs Atezolizumab, Tecentriq, Bevacizumab, Avastin, Erlotinib, and Tarceva for kidney cancer?
Is the triple drug therapy for kidney cancer safe for humans?
The safety of the drugs Atezolizumab, Bevacizumab, and Erlotinib has been studied in various conditions. Bevacizumab, for example, has been approved for use in kidney cancer and is generally safe, but it can cause side effects like bleeding, high blood pressure, and blood clots. Managing these side effects is important to ensure patient safety and quality of life during treatment.46789
How is the triple drug therapy for kidney cancer unique?
The triple drug therapy for kidney cancer combines Atezolizumab, Bevacizumab, and Erlotinib, which is unique because it targets multiple pathways involved in cancer growth and spread, including the immune system, blood vessel formation, and cell growth signals, potentially offering a more comprehensive approach than single or dual therapies.25101112
What is the purpose of this trial?
This phase II trial studies the effects of combination therapy with bevacizumab, erlotinib, and atezolizumab in treating patients with hereditary leiomyomatosis and kidney cancer that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Bevacizumab is in a class of medications called antiangiogenic agents. They work by stopping the formation of blood vessels that bring oxygen and nutrients to tumors. This may slow the growth and spread of tumors. Erlotinib is in a class of medications called kinase inhibitors. It works by blocking the action of a protein called EGFR that signals cancer cells to multiply. This helps slow or stop the spread of cancer cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Combination therapy with bevacizumab, erlotinib, and atezolizumab may stabilize or shrink advanced hereditary leiomyomatosis and kidney cancer.
Research Team
Ramaprasad Srinivasan
Principal Investigator
National Cancer Institute LAO
Eligibility Criteria
This trial is for individuals aged 12 or older with advanced kidney cancer, including hereditary leiomyomatosis and renal cell carcinoma. Participants must have measurable disease, acceptable organ function, no more than two prior VEGF-targeted treatments, and no recent use of certain medications or therapies. Those with treated brain metastases stable for at least 3 months can join. Pregnant women and tobacco users who cannot quit are excluded.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive bevacizumab, erlotinib, and atezolizumab in 21-day cycles
Follow-up
Participants are monitored for safety and effectiveness after treatment
Treatment Details
Interventions
- Atezolizumab
- Bevacizumab
- Erlotinib
Atezolizumab is already approved in United States, European Union for the following indications:
- Melanoma
- Hepatocellular carcinoma
- Small cell lung cancer
- Non-small cell lung cancer
- Urothelial carcinoma
- Melanoma
- Hepatocellular carcinoma
- Small cell lung cancer
- Non-small cell lung cancer
- Urothelial carcinoma
Find a Clinic Near You
Who Is Running the Clinical Trial?
National Cancer Institute (NCI)
Lead Sponsor